Differential proteomic profiling of chordomas and analysis of prognostic factors

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 720-727

  Zhou, Hua ^a   Chen, Chang Bao ^a   Lan, Jie ^a   Liu, Chao ^b   Liu, Xiao Guang ^a   Jiang, Liang ^a   Wei, Feng ^a   Ma, Qing Jun ^a   Dang, Geng Ting ^a   Liu, Zhong Jun ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b BEIHANG UNIVERSITY   (China)

Author keywords

cervical spine; chordoma; prognosis; proteomics; spinal tumor

Indexed keywords

ALPHA ENOLASE; GLYCOPROTEIN GP 96; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURGERY; CHILD; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; SPINE TUMOR; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CHORDOMA; DNA-BINDING PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 78649650772     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21674     Document Type: Article

References (58)

1. Casali PG, Stacchiotti S, Sangalli C, et al.: Chordoma. Curr Opin Oncol 2007; 19: 367-370.
2. McMaster ML, Goldstein AM, Bromley CM, et al.: Chordoma: Incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12: 1-11.
3. Boriani S, Chevalley F, Weinstein JN, et al.: Chordoma of the spine above the sacruma - Treatment and outcome in 21 cases. Spine 1996; 21: 1569-1577.
4. Boriani S, Bandiera S, Biagini R, et al.: Chordoma of the mobile spine: Fifty years of experience. Spine 2006; 31: 493-503.
5. Sciubba DM, Chi JH, Rhines LD, et al.: Chordoma of the spinal column. Neurosurg Clin N Am 2008; 19: 5-15.
6. Tamborini E, Miselli F, Negri T, et al.: Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006; 12: 6920-6928.
7. Tai PT, Craighead P, Liem SK, et al.: Management issues in chordoma: A case series. Clin Oncol 2000; 12: 80-86.
8. Chugh R, Tawbi H, Lucas DR, et al.: Chordoma: The nonsarcoma primary bone tumor. Oncologist 2007; 12: 1344-1350.
9. Baratti D, Gronchi A, Pennacchioli E, et al.: Chordoma: Natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003; 10: 291-296. (Pubitemid 40486963)
10. DeLaney TF, Chen GT, Mauceri TC, et al.: Intraoperative dural irradiation by customized (192)iridium and (90)yttrium brachytherapy plaques. Int J Radiat Oncol Biol Phys 2003; 57: 239-245.
11. DeLaney TF, Liebsch NJ, Pedlow FX, et al.: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009; 74: 732-739.
12. Park L, DeLaney TF, Liebsch NJ, et al.: Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006; 65: 1514-1521.
13. Imai R, Kamada T, Tsuji H, et al.: Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res 2004; 10: 5741-5746. (Pubitemid 39180950)
14. Serizawa I, Imai R, Kamada T, et al.: Changes in tumor volume of sacral chordoma after carbon ion radiotherapy. J Comput Assist Tomogr 2009; 33: 795-798.
15. Bergh P, Kindblom LG, Gunterberg B, et al.: Prognostic factors in chordoma of the sacrum and mobile spinea - A study of 39 patients. Cancer 2000; 88: 2122-2134.
16. Bjornsson J, Wold LE, Ebersold MJ, et al.: Chordoma of the mobile spinea clinicopathologic analysis of 40 patients. Cancer 1993; 71: 735-740.
17. Cheng EY, Ozerdemoglu RA, Transfeldt EE, et al.: Lumbosacral chordomaa - Prognostic factors and treatment. Spine 1999; 24: 1639-1645.
18. Enneking WF, Spanier SS, Goodman MA:, The classic: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 2003; 415: 4-18.
19. Chetty R, Levin CV, Kalan MR:, Chordomaa - A 20-year clinicopathological review of the experience at Groote Schuur Hospital, Cape-Town. J Surg Oncol 1991; 46: 261-264.
20. Deniz ML, Kilic T, Almaata I, et al.: Expression of growth factors and structural proteins in chordomas: Basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence. Neurosurgery 2002; 51: 753-760.
21. Naka T, Boltze C, Kuester D, et al.: Alterations of G(1)-S checkpoint in chordoma: The prognostic impact of p53 overexpression. Cancer 2005; 104: 1255-1263.
22. Schwab JH, Boland PJ, Agaram NP, et al.: Chordoma and chondrosarcoma gene profile: Implications for immunotherapy. Cancer Immunol Immunother 2009; 58: 339-349.
23. Gokaslan ZL, Chintala SK, York JE, et al.: Expression and localization of urokinase-type plasminogen activator in human spinal column tumors. Clin Exp Metastasis 1998; 16: 713-719.
24. Gokaslan ZL, Chintala SK, York JE, et al.: Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin Exp Metastasis 1998; 16: 721-728.
25. Christofk HR, Vander Heiden MG, Harris MH, et al.: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
26. Innes K, Hooper J, Bramley M, et al.: Creation of a clinical classification. International statistical classification of diseases and related health problemsa - 10th revision, Australian modification (ICD-10-AM). Health Inf Manage 1997; 27: 31-38.
27. Blum H, Beier H, Gross HJ:, Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 1987; 8: 93-99.
28. Altenberg B, Greulich KO:, Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004; 84: 1014-1020.
29. Chang GC, Liu KJ, Hsieh CL, et al.: Identification of alpha-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes. Clin Cancer Res 2006; 12: 5746-5754.
30. Langer R, Feith M, Siewert JR, et al.: Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer 2008; 8: 70.
31. Rhines LD, Fourney DR, Siadati A, et al.: En bloc resection of multilevel cervical chordoma with C-2 involvementa - Case report and description of operative technique. J Neurosurg Spine 2005; 2: 199-205.
32. Carpentier A, Polivka M, Blanquet A, et al.: Suboccipital and cervical chordomas: The value of aggressive treatment at first presentation of the disease. J Neurosurg 2002; 97: 1070-1077.
33. Piper JG, Menezes AH:, Management strategies for tumors of the axis vertebra. J Neurosurg 1996; 84: 543-551.
34. Zileli M, Kilincer C, Ersahin Y, et al.: Primary tumors of the cervical spine: A retrospective review of 35 surgically managed cases. Spine J 2007; 7: 165-173.
35. Tomita K, Kawahara N, Baba H, et al.: Total en bloc spondylectomya - A new surgical technique for primary malignant vertebral tumors. Spine 1997; 22: 324-333.
36. Gallia GL, Haque R, Garonzik I, et al.: Spinal pelvic reconstruction after total sacrectomy for en bloc resection of a giant sacral chordoma. J Neurosurg Spine 2005; 3: 501-506.
37. Kawahara N, Tomita K, Murakami H, et al.: Total en bloc spondylectomy for spinal tumors: Surgical techniques and related basic background. Orthop Clin North Am 2009; 40: 47-63.
38. Kawahara N, Murakami H, Yoshida A, et al.: Reconstruction after total sacrectomy using a new instrumentation techniquea - A biomechanical comparison. Spine 2003; 28: 1567-1572.
39. Tomita K, Kawahara N, Murakami H, et al.: Total en bloc spondylectomy for spinal tumors: Improvement of the technique and its associated basic background. J Orthop Sci 2006; 11: 3-12.
40. Schwab JH, Healey JH, Boland PJ:, The surgical management of sacral chordoma. Ann Surg Oncol 2008; 15: 65-66.
41. Bandiera S, Boriani S, Donthineni R, et al.: Complications of en bloc resections in the spine. Orthop Clin North Am 2009; 40: 125-131.
42. Berven S, Zurakowski D, Mankin HJ, et al.: Clinical outcome in chordomaa - Utility of flow cytometry in DNA determination. Spine 2002; 27: 374-379.
43. Kawahara N, Tomita K, Matsumoto T, et al.: Total en bloc spondylectomy for primary malignant vertebral tumors. Chir Organi Mov 1998; 83: 73-86.
44. Palesty JA, Kraybill WG:, Developments in the management of extremity soft tissue sarcomas. Cancer Invest 2005; 23: 692-699.
45. Liu Z, Dang G, Ma Q, et al.: Spinal tumors treated with total spondylectomy and spinal stability reconstruction (in Chinese). Zhonghua Gu Ke Za Zhi 2001; 21: 646-649.
46. Jiang L, Liu Z, Liu X, et al.: Upper cervical spine chordoma of C2-C3. Eur Spine J 2009; 18: 293-300.
47. Boriani S, Biagini R, Delure F, et al.: En bloc resections of bone tumors of the thoracolumbar spinea - A preliminary report on 29 patients. Spine 1996; 21: 1927-1931.
48. Boriani S, Biagini R, De Iure F, et al.: Resection surgery in the treatment of vertebral tumors. Chir Organi Mov 1998; 83: 53-64.
49. Chi JH, Sciubba DM, Rhines LD, et al.: Surgery for primary vertebral tumors: En bloc versus intralesional resection. Neurosurg Clin N Am 2008; 19: 111-117.
50. Barrenechea IJ, Perin NI, Triana A, et al.: Surgical management of chordomas of the cervical spine. J Neurosurg Spine 2007; 6: 398-406.
51. Zhou H, Liu Z, Liu C, et al.: Cervical chordoma in childhood without typical vertebral bony destruction: Case report and review of the literature. Spine 2009; 34: E493-E497.
52. Leitner Y, Shabat S, Boriani L, et al.: En bloc resection of a C4 chordoma: Surgical technique. Eur Spine J 2007; 16: 2238-2242.
53. Fujita T, Kawahara N, Matsumoto T, et al.: Chordoma in the cervical spine managed with en bloc excision. Spine 1999; 24: 1848-1851.
54. Neo M, Asato R, Honda K, et al.: Transmaxillary and transmandibular approach to a C1 chordoma. Spine 2007; 32: E236-E239.
55. Liu Z, Dang G, Ma Q, et al.: Atlantoaxial tumors treated with redical resection (in Chinese). Beijing Da Xue Xue Bao 2002; 34: 653-655.
56. York JE, Kaczaraj A, Abi-Said D, et al.: Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 1999; 44: 74-79.
57. Fourney DR, Rhines LD, Hentschel SJ, et al.: En bloc resection of primary sacral tumors: Classification of surgical approaches and outcome. J Neurosurg Spine 2005; 3: 111-122.
58. Azzarelli A, Quagiuolo V, Cerasoli S, et al.: Chordomaa - Natural history and treatment results in 33 cases. J Surg Oncol 1988; 37: 185-191.